Media & Advertising
7/13/13 - Genentech Secures FDA Priority Review for Perjeta Regimen Prior to Surgery
Have an interest in this Story?
Sign Up for Real-Time email updates
July 13, 2013
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early stag...
Read Full Article
Leave a Comment:
You must be logged in to leave a comment
Most Read Biotech Articles
Australian Islamic extremist Robert 'Musa' Cerantonio reportedly deported from Philippines
- Melbourne Age
First Midwest Bancorp, Inc. Announces 2014 Second Quarter Results
Stopping for a Byte to Eat: The Influence of Technology on the Hungry American
Best Vitamin C Serum for Wrinkles List Complied for Women at Consumer...
Second Circuit Reinstates Asbestos Judgment Against Travelers
- Insurance Broadcasting
Sylvia M. Romagosa, MBA
Licensed Real Estate Broker
Real Estate Industry
Corporate Marketing Manager
View more profiles
Access dozens of premium and subscriptions sites
Build a News Circle
Get News Briefings
Congoo News Home
Get the Netpass
Copyright ©2014 Congoo.com. All Rights Reserved.